Target Validation Information
TTD ID	T05409
Target Name	Neutral endopeptidase (MME)
Type of Target	Clinical trial
Drug Potency against Target	Ilepatril	Drug Info	Ki = 5 nM	[4]
	Omapatrilat	Drug Info	IC50 = 5 nM	[1]
	9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid	Drug Info	IC50 = 4 nM	[3]
	CGS-26303	Drug Info	IC50 = 0.9 nM
	CGS-314447	Drug Info	IC50 = 6.9 nM
	SCH-54470	Drug Info	IC50 = 90 nM	[2]
	SQ-26332	Drug Info	IC50 = 400 nM	[1]
References
REF 1	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
REF 2	Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20.
REF 3	Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor. J Med Chem. 1993 Nov 26;36(24):3821-8.
REF 4	Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res. 2003 Nov 1;60(2):447-54.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.